Review



plgf 2  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    R&D Systems plgf 2
    Inhibitory effects of PB101 on angiogenesis. ( A ) Endothelial cell chemotactic migration assay. EA.hy926 cells (1 × 10 5 , n = 3) were loaded in the upper chambers of Transwell inserts and chemoattracted by VEGF (100 ng/mL) <t>or</t> <t>PlGF-2</t> (40 ng/mL) with or without PB101 (2 or 5 μg/mL) in the lower chambers. The cells that migrated to the underside of the Transwell chamber were manually counted, and the results are presented as a percentage of the untreated control (none). ( B ) Wounding migration of endothelial cells. EA.hy926 cells (4 × 10 5 , n = 5) seeded on a 6-well plate were wounded using pipette tips and treated with VEGF (200 ng/mL) or PlGF-2 (100 ng/mL) with or without PB101 (2 or 5 μg/mL). The cells that crossed the reference lines (red dashed lines) were counted as migrated cells. ( C ) Capillary tube formation by endothelial cells. EA.hy926 cells (3 × 10 4 , n = 3–4) were seeded on a Matrigel-coated 96-well plate and incubated with VEGF (500 ng/mL) or PlGF-2 (500 ng/mL) with or without PB101 (10 or 50 μg/mL). The tube formation area was measured and is presented as an arbitrary unit (a.u.). The cellular images are representative of three independent experiments. Scale bar, 200 μm. The bar graphs present the mean and SEM. The p-values were determined via one-way ANOVA with Tukey's multiple comparisons test. ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001 vs. untreated controls. # p < 0.05, ## p < 0.01 vs. PlGF- or VEGF-treated positive controls. ( D and E ) Suppression of recombinant PlGF-induced angiogenesis by PB101 in a Matrigel plug assay. C57BL/6 mice (n = 3, total 12 mice) were injected subcutaneously with Matrigel mixed with VEGF (500 ng/mL) or recombinant PlGF-2 (200 ng/mL) with or without PB101 (50 μg/mL) (D). Mice were injected with vehicle or PB101 (50 mg/kg) every day. To assess the effects of PlGF-overexpressing T cells, CD4 + T cells isolated from PlGF transgenic (PlGF Tg) mice were stimulated with anti-CD3/CD28 Abs for 48 h. PlGF Tg CD4 + T cells (5 × 10 5 ) and their culture supernatants were incorporated into Matrigel with or without PB101 (50 μg/mL) (E). C57BL/6 mice (n = 3) were subcutaneously injected with these Matrigel plugs and received daily injections of Fc vehicle or PB101 (50 mg/kg). After 14 days, the vascularity of the Matrigel plugs was evaluated through visual assessment and H&E staining of the tissue sections. Scale bars, 500 nm (top) for Matrigel plugs, and 100 (middle) and 1000 (bottom) μm for H&E. The boxed areas in the upper panels of the H&E-stained images are shown at higher magnification in the lower panels. ( F ) Immunohistochemical staining of the Matrigel plugs was performed using an anti-F4/80 Ab to assess macrophage infiltration. The macrophages were manually counted in three randomly selected fields per section of total nine sites per group. Scale bars, 100 μm. The bar graphs present the mean and SEM. ∗∗∗∗p < 0.0001 vs. untreated controls. ### p < 0.001 and #### p < 0.0001 vs. PB101-untreated positive controls. The p-values were determined via Kruskal–Wallis with Dunn's multiple comparisons test.
    Plgf 2, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 12 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+plgf+2/Recombinant+Mouse+PlGF-2+Protein/pmc13015212-72-20-25
    Average 94 stars, based on 12 article reviews
    plgf 2 - by Bioz Stars, 2026-10
    94/100 stars

    Images

    1) Product Images from "The therapeutic effects of the VEGF decoy receptor fusion protein VEGF-Grab in chronic inflammatory diseases"

    Article Title: The therapeutic effects of the VEGF decoy receptor fusion protein VEGF-Grab in chronic inflammatory diseases

    Journal: eBioMedicine

    doi: 10.1016/j.ebiom.2026.106216

    Inhibitory effects of PB101 on angiogenesis. ( A ) Endothelial cell chemotactic migration assay. EA.hy926 cells (1 × 10 5 , n = 3) were loaded in the upper chambers of Transwell inserts and chemoattracted by VEGF (100 ng/mL) or PlGF-2 (40 ng/mL) with or without PB101 (2 or 5 μg/mL) in the lower chambers. The cells that migrated to the underside of the Transwell chamber were manually counted, and the results are presented as a percentage of the untreated control (none). ( B ) Wounding migration of endothelial cells. EA.hy926 cells (4 × 10 5 , n = 5) seeded on a 6-well plate were wounded using pipette tips and treated with VEGF (200 ng/mL) or PlGF-2 (100 ng/mL) with or without PB101 (2 or 5 μg/mL). The cells that crossed the reference lines (red dashed lines) were counted as migrated cells. ( C ) Capillary tube formation by endothelial cells. EA.hy926 cells (3 × 10 4 , n = 3–4) were seeded on a Matrigel-coated 96-well plate and incubated with VEGF (500 ng/mL) or PlGF-2 (500 ng/mL) with or without PB101 (10 or 50 μg/mL). The tube formation area was measured and is presented as an arbitrary unit (a.u.). The cellular images are representative of three independent experiments. Scale bar, 200 μm. The bar graphs present the mean and SEM. The p-values were determined via one-way ANOVA with Tukey's multiple comparisons test. ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001 vs. untreated controls. # p < 0.05, ## p < 0.01 vs. PlGF- or VEGF-treated positive controls. ( D and E ) Suppression of recombinant PlGF-induced angiogenesis by PB101 in a Matrigel plug assay. C57BL/6 mice (n = 3, total 12 mice) were injected subcutaneously with Matrigel mixed with VEGF (500 ng/mL) or recombinant PlGF-2 (200 ng/mL) with or without PB101 (50 μg/mL) (D). Mice were injected with vehicle or PB101 (50 mg/kg) every day. To assess the effects of PlGF-overexpressing T cells, CD4 + T cells isolated from PlGF transgenic (PlGF Tg) mice were stimulated with anti-CD3/CD28 Abs for 48 h. PlGF Tg CD4 + T cells (5 × 10 5 ) and their culture supernatants were incorporated into Matrigel with or without PB101 (50 μg/mL) (E). C57BL/6 mice (n = 3) were subcutaneously injected with these Matrigel plugs and received daily injections of Fc vehicle or PB101 (50 mg/kg). After 14 days, the vascularity of the Matrigel plugs was evaluated through visual assessment and H&E staining of the tissue sections. Scale bars, 500 nm (top) for Matrigel plugs, and 100 (middle) and 1000 (bottom) μm for H&E. The boxed areas in the upper panels of the H&E-stained images are shown at higher magnification in the lower panels. ( F ) Immunohistochemical staining of the Matrigel plugs was performed using an anti-F4/80 Ab to assess macrophage infiltration. The macrophages were manually counted in three randomly selected fields per section of total nine sites per group. Scale bars, 100 μm. The bar graphs present the mean and SEM. ∗∗∗∗p < 0.0001 vs. untreated controls. ### p < 0.001 and #### p < 0.0001 vs. PB101-untreated positive controls. The p-values were determined via Kruskal–Wallis with Dunn's multiple comparisons test.
    Figure Legend Snippet: Inhibitory effects of PB101 on angiogenesis. ( A ) Endothelial cell chemotactic migration assay. EA.hy926 cells (1 × 10 5 , n = 3) were loaded in the upper chambers of Transwell inserts and chemoattracted by VEGF (100 ng/mL) or PlGF-2 (40 ng/mL) with or without PB101 (2 or 5 μg/mL) in the lower chambers. The cells that migrated to the underside of the Transwell chamber were manually counted, and the results are presented as a percentage of the untreated control (none). ( B ) Wounding migration of endothelial cells. EA.hy926 cells (4 × 10 5 , n = 5) seeded on a 6-well plate were wounded using pipette tips and treated with VEGF (200 ng/mL) or PlGF-2 (100 ng/mL) with or without PB101 (2 or 5 μg/mL). The cells that crossed the reference lines (red dashed lines) were counted as migrated cells. ( C ) Capillary tube formation by endothelial cells. EA.hy926 cells (3 × 10 4 , n = 3–4) were seeded on a Matrigel-coated 96-well plate and incubated with VEGF (500 ng/mL) or PlGF-2 (500 ng/mL) with or without PB101 (10 or 50 μg/mL). The tube formation area was measured and is presented as an arbitrary unit (a.u.). The cellular images are representative of three independent experiments. Scale bar, 200 μm. The bar graphs present the mean and SEM. The p-values were determined via one-way ANOVA with Tukey's multiple comparisons test. ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001 vs. untreated controls. # p < 0.05, ## p < 0.01 vs. PlGF- or VEGF-treated positive controls. ( D and E ) Suppression of recombinant PlGF-induced angiogenesis by PB101 in a Matrigel plug assay. C57BL/6 mice (n = 3, total 12 mice) were injected subcutaneously with Matrigel mixed with VEGF (500 ng/mL) or recombinant PlGF-2 (200 ng/mL) with or without PB101 (50 μg/mL) (D). Mice were injected with vehicle or PB101 (50 mg/kg) every day. To assess the effects of PlGF-overexpressing T cells, CD4 + T cells isolated from PlGF transgenic (PlGF Tg) mice were stimulated with anti-CD3/CD28 Abs for 48 h. PlGF Tg CD4 + T cells (5 × 10 5 ) and their culture supernatants were incorporated into Matrigel with or without PB101 (50 μg/mL) (E). C57BL/6 mice (n = 3) were subcutaneously injected with these Matrigel plugs and received daily injections of Fc vehicle or PB101 (50 mg/kg). After 14 days, the vascularity of the Matrigel plugs was evaluated through visual assessment and H&E staining of the tissue sections. Scale bars, 500 nm (top) for Matrigel plugs, and 100 (middle) and 1000 (bottom) μm for H&E. The boxed areas in the upper panels of the H&E-stained images are shown at higher magnification in the lower panels. ( F ) Immunohistochemical staining of the Matrigel plugs was performed using an anti-F4/80 Ab to assess macrophage infiltration. The macrophages were manually counted in three randomly selected fields per section of total nine sites per group. Scale bars, 100 μm. The bar graphs present the mean and SEM. ∗∗∗∗p < 0.0001 vs. untreated controls. ### p < 0.001 and #### p < 0.0001 vs. PB101-untreated positive controls. The p-values were determined via Kruskal–Wallis with Dunn's multiple comparisons test.

    Techniques Used: Migration, Control, Transferring, Incubation, Recombinant, Matrigel Assay, Injection, Isolation, Transgenic Assay, Staining, Immunohistochemical staining

    Suppressive effects of VEGF-Grab on the aggressiveness of RA-FLSs. ( A ) Chemotactic migration of RA-FLSs in Transwell inserts. RA-FLSs (1 × 10 5 , n = 4) were loaded in the upper chambers of Transwell inserts. Culture media supplemented with 1% FBS and recombinant PlGF-2 (100 ng/mL), with or without PB101 (5 or 10 μg/mL), were loaded in the lower chamber. After 12 h, cells that migrated to the lower side of the Transwell membrane were manually counted. Scale bars, 1000 μm (upper panel) and 200 μm (lower panel). ( B ) Wounding migration assay with RA-FLSs. RA-FLSs (1.5 × 10 5 , n = 4) were seeded on 6-well plates, scratched with pipette tips, and treated with recombinant PlGF-2 (100 ng/mL), with and without PB101 (2 or 10 μg/mL), for 12 h. The cells that migrated across the reference lines (red dashed lines) were manually counted. Scale bars, 200 μm. The bar graphs present the mean and SEM. ∗∗p < 0.01 vs. untreated controls. # p < 0.05 and ## p < 0.01 vs. PlGF-treated positive controls. The p-values were determined via one-way ANOVA with Tukey's multiple comparisons test. ( C ) RA-FLS invasion into cartilage in a humanised synovitis model. RA-FLSs (2 × 10 6 ) were resuspended in a medium containing PlGF-2 (100 ng/mL) or a medium with PlGF-2 (100 ng/mL) and PB101 (2 μg/mL). These RA-FLSs were co-implanted with human cartilage into the left flanks (primary) of SCID mice (n = 3, total 6 mice). In the right flanks (contralateral), cartilage of the same size was implanted without RA-FLSs. For 60 days after cartilage implantation, the mice were injected intraperitoneally with vehicle or PB101 (2 mg/kg) twice a week. ( D ) Following excision, the cartilage samples were processed for H&E staining to evaluate invasion. The scoring protocol is detailed in the Materials and Methods section. For each implanted cartilage, three distinct regions were evaluated independently, and all regional values are shown as individual data points. Scale bars, 100 μm. The bar graphs present the mean and SEM. ∗p < 0.05 vs. vehicle controls. The p-values were determined via an unpaired t -test.
    Figure Legend Snippet: Suppressive effects of VEGF-Grab on the aggressiveness of RA-FLSs. ( A ) Chemotactic migration of RA-FLSs in Transwell inserts. RA-FLSs (1 × 10 5 , n = 4) were loaded in the upper chambers of Transwell inserts. Culture media supplemented with 1% FBS and recombinant PlGF-2 (100 ng/mL), with or without PB101 (5 or 10 μg/mL), were loaded in the lower chamber. After 12 h, cells that migrated to the lower side of the Transwell membrane were manually counted. Scale bars, 1000 μm (upper panel) and 200 μm (lower panel). ( B ) Wounding migration assay with RA-FLSs. RA-FLSs (1.5 × 10 5 , n = 4) were seeded on 6-well plates, scratched with pipette tips, and treated with recombinant PlGF-2 (100 ng/mL), with and without PB101 (2 or 10 μg/mL), for 12 h. The cells that migrated across the reference lines (red dashed lines) were manually counted. Scale bars, 200 μm. The bar graphs present the mean and SEM. ∗∗p < 0.01 vs. untreated controls. # p < 0.05 and ## p < 0.01 vs. PlGF-treated positive controls. The p-values were determined via one-way ANOVA with Tukey's multiple comparisons test. ( C ) RA-FLS invasion into cartilage in a humanised synovitis model. RA-FLSs (2 × 10 6 ) were resuspended in a medium containing PlGF-2 (100 ng/mL) or a medium with PlGF-2 (100 ng/mL) and PB101 (2 μg/mL). These RA-FLSs were co-implanted with human cartilage into the left flanks (primary) of SCID mice (n = 3, total 6 mice). In the right flanks (contralateral), cartilage of the same size was implanted without RA-FLSs. For 60 days after cartilage implantation, the mice were injected intraperitoneally with vehicle or PB101 (2 mg/kg) twice a week. ( D ) Following excision, the cartilage samples were processed for H&E staining to evaluate invasion. The scoring protocol is detailed in the Materials and Methods section. For each implanted cartilage, three distinct regions were evaluated independently, and all regional values are shown as individual data points. Scale bars, 100 μm. The bar graphs present the mean and SEM. ∗p < 0.05 vs. vehicle controls. The p-values were determined via an unpaired t -test.

    Techniques Used: Migration, Recombinant, Membrane, Transferring, Injection, Staining

    Related Articles

    Blocking Assay:

    Article Title: Photoreceptor avascular privilege is shielded by soluble VEGF receptor-1
    Article Snippet: A 2 mg/ml sample of mouse FLT-1-Fc protein (471-F1; R&D Systems, Minneapolis, MN) was immobilized on an ELISA plate. .. After blocking with 1% BSA, the plate was incubated in 2 ng/ml mouse VEGF-A (493-MV-005; R&D) or mouse PlGF-2 (465-PL-010; R&D) at room temperature (RT) for 2 hr. .. Then, each well was incubated in ( A ) 2 ng/ml mouse VEGF-A, ( B ) 2 ng/ml mouse VEGF-A + 5 mg/ml isotype IgG, ( C ) 2 ng/ml mouse VEGF-A + 5 mg/ml anti-FLT-1 IgG (AF471; R&D), ( D ) 2 ng/ml mouse PlGF-2, ( E ) 2 ng/ml mouse PlGF-2 + 5 mg/ml isotype IgG, or ( F ) 2 ng/ml mouse PlGF-2 + 5 mg/ml anti-FLT-1 IgG at RT for 6 hr.

    Incubation:

    Article Title: Photoreceptor avascular privilege is shielded by soluble VEGF receptor-1
    Article Snippet: A 2 mg/ml sample of mouse FLT-1-Fc protein (471-F1; R&D Systems, Minneapolis, MN) was immobilized on an ELISA plate. .. After blocking with 1% BSA, the plate was incubated in 2 ng/ml mouse VEGF-A (493-MV-005; R&D) or mouse PlGF-2 (465-PL-010; R&D) at room temperature (RT) for 2 hr. .. Then, each well was incubated in ( A ) 2 ng/ml mouse VEGF-A, ( B ) 2 ng/ml mouse VEGF-A + 5 mg/ml isotype IgG, ( C ) 2 ng/ml mouse VEGF-A + 5 mg/ml anti-FLT-1 IgG (AF471; R&D), ( D ) 2 ng/ml mouse PlGF-2, ( E ) 2 ng/ml mouse PlGF-2 + 5 mg/ml isotype IgG, or ( F ) 2 ng/ml mouse PlGF-2 + 5 mg/ml anti-FLT-1 IgG at RT for 6 hr.

    Recombinant:

    Article Title: Placenta Growth Factor (PlGF), a Novel Inducer of Plasminogen Activator Inhibitor-1 (PAI-1) in Sickle Cell Disease (SCD)
    Article Snippet: .. Human recombinant PlGF, mouse PlGF-2, and human PAI-1 immunoassay kits were obtained from R&D Systems (Minneapolis, MN). .. Pharmacological inhibitors of cell signaling ( supplemental Table S1 ) were obtained from Tocris Bioscience (Ellisville, MO), and [ 32 P]UTP was obtained from MP Biomedicals (Solon, OH).

    Clinical Proteomics:

    Article Title: MELANOCORTIN-4 RECEPTOR DEFICIENCY ATTENUATES PLACENTAL ISCHEMIA-INDUCED HYPERTENSION IN PREGNANT RATS
    Article Snippet: Biochemistry Plasma levels of the adipokines leptin and adiponectin were examined using Quantikine enzyme-linked immunosorbent assay (ELISA) kits from R&D Systems (Minneapolis, MN, USA - MOB00 and RRP300, respectively). .. As reduced bioavailability of placental growth factor (PlGF) mediates the development of placental ischemia-induced hypertension 30 , plasma PlGF levels were also quantified by an ELISA kit from R&D Systems detecting mouse PlGF-2 (Minneapolis, MN, USA - MP200). ..

    Article Title: High-fat diet from parental generation exaggerates body and adipose tissue weights in pregnant offspring
    Article Snippet: Plasma levels of the adipokine, leptin, were examined using a Quantikine enzyme-linked immunosorbent assay (ELISA) from R&D Systems (Minneapolis, MN, USA—MOB00). .. Plasma free PlGF levels were also quantified by an ELISA kit from R&D Systems detecting mouse PlGF-2 (Minneapolis, MN, USA—MP200). .. Data were graphed and analyzed using GraphPad Prism version 8.1.2 (La Jolla, CA, USA).

    Article Title: Melanocortin-4 Receptor Deficiency Attenuates Placental Ischemia-Induced Hypertension in Pregnant Rats
    Article Snippet: Plasma levels of the adipokines leptin and adiponectin were examined using Quantikine ELISA kits from R&D Systems (Minneapolis, MN, MOB00 and RRP300, respectively). .. As reduced bioavailability of PlGF (placental growth factor) mediates the development of placental ischemia-induced hypertension,30 plasma PlGF levels were also quantified by an ELISA kit from R&D Systems detecting mouse PlGF-2 (Minneapolis, MN—MP200). .. Using the National Center for Biotechnology Information Protein Basic Local Alignment Search Tool software, it was found that mouse and rat PlGF-2 have 91% alignment (https://www.blast.ncbi.nlm.nih.gov/www.Blast.cgi).

    Enzyme-linked Immunosorbent Assay:

    Article Title: MELANOCORTIN-4 RECEPTOR DEFICIENCY ATTENUATES PLACENTAL ISCHEMIA-INDUCED HYPERTENSION IN PREGNANT RATS
    Article Snippet: Biochemistry Plasma levels of the adipokines leptin and adiponectin were examined using Quantikine enzyme-linked immunosorbent assay (ELISA) kits from R&D Systems (Minneapolis, MN, USA - MOB00 and RRP300, respectively). .. As reduced bioavailability of placental growth factor (PlGF) mediates the development of placental ischemia-induced hypertension 30 , plasma PlGF levels were also quantified by an ELISA kit from R&D Systems detecting mouse PlGF-2 (Minneapolis, MN, USA - MP200). ..

    Article Title: High-fat diet from parental generation exaggerates body and adipose tissue weights in pregnant offspring
    Article Snippet: Plasma levels of the adipokine, leptin, were examined using a Quantikine enzyme-linked immunosorbent assay (ELISA) from R&D Systems (Minneapolis, MN, USA—MOB00). .. Plasma free PlGF levels were also quantified by an ELISA kit from R&D Systems detecting mouse PlGF-2 (Minneapolis, MN, USA—MP200). .. Data were graphed and analyzed using GraphPad Prism version 8.1.2 (La Jolla, CA, USA).

    Article Title: Melanocortin-4 Receptor Deficiency Attenuates Placental Ischemia-Induced Hypertension in Pregnant Rats
    Article Snippet: Plasma levels of the adipokines leptin and adiponectin were examined using Quantikine ELISA kits from R&D Systems (Minneapolis, MN, MOB00 and RRP300, respectively). .. As reduced bioavailability of PlGF (placental growth factor) mediates the development of placental ischemia-induced hypertension,30 plasma PlGF levels were also quantified by an ELISA kit from R&D Systems detecting mouse PlGF-2 (Minneapolis, MN—MP200). .. Using the National Center for Biotechnology Information Protein Basic Local Alignment Search Tool software, it was found that mouse and rat PlGF-2 have 91% alignment (https://www.blast.ncbi.nlm.nih.gov/www.Blast.cgi).



    Similar Products

    plgf 2  (R&D Systems)
    94
    R&D Systems plgf 2
    Inhibitory effects of PB101 on angiogenesis. ( A ) Endothelial cell chemotactic migration assay. EA.hy926 cells (1 × 10 5 , n = 3) were loaded in the upper chambers of Transwell inserts and chemoattracted by VEGF (100 ng/mL) <t>or</t> <t>PlGF-2</t> (40 ng/mL) with or without PB101 (2 or 5 μg/mL) in the lower chambers. The cells that migrated to the underside of the Transwell chamber were manually counted, and the results are presented as a percentage of the untreated control (none). ( B ) Wounding migration of endothelial cells. EA.hy926 cells (4 × 10 5 , n = 5) seeded on a 6-well plate were wounded using pipette tips and treated with VEGF (200 ng/mL) or PlGF-2 (100 ng/mL) with or without PB101 (2 or 5 μg/mL). The cells that crossed the reference lines (red dashed lines) were counted as migrated cells. ( C ) Capillary tube formation by endothelial cells. EA.hy926 cells (3 × 10 4 , n = 3–4) were seeded on a Matrigel-coated 96-well plate and incubated with VEGF (500 ng/mL) or PlGF-2 (500 ng/mL) with or without PB101 (10 or 50 μg/mL). The tube formation area was measured and is presented as an arbitrary unit (a.u.). The cellular images are representative of three independent experiments. Scale bar, 200 μm. The bar graphs present the mean and SEM. The p-values were determined via one-way ANOVA with Tukey's multiple comparisons test. ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001 vs. untreated controls. # p < 0.05, ## p < 0.01 vs. PlGF- or VEGF-treated positive controls. ( D and E ) Suppression of recombinant PlGF-induced angiogenesis by PB101 in a Matrigel plug assay. C57BL/6 mice (n = 3, total 12 mice) were injected subcutaneously with Matrigel mixed with VEGF (500 ng/mL) or recombinant PlGF-2 (200 ng/mL) with or without PB101 (50 μg/mL) (D). Mice were injected with vehicle or PB101 (50 mg/kg) every day. To assess the effects of PlGF-overexpressing T cells, CD4 + T cells isolated from PlGF transgenic (PlGF Tg) mice were stimulated with anti-CD3/CD28 Abs for 48 h. PlGF Tg CD4 + T cells (5 × 10 5 ) and their culture supernatants were incorporated into Matrigel with or without PB101 (50 μg/mL) (E). C57BL/6 mice (n = 3) were subcutaneously injected with these Matrigel plugs and received daily injections of Fc vehicle or PB101 (50 mg/kg). After 14 days, the vascularity of the Matrigel plugs was evaluated through visual assessment and H&E staining of the tissue sections. Scale bars, 500 nm (top) for Matrigel plugs, and 100 (middle) and 1000 (bottom) μm for H&E. The boxed areas in the upper panels of the H&E-stained images are shown at higher magnification in the lower panels. ( F ) Immunohistochemical staining of the Matrigel plugs was performed using an anti-F4/80 Ab to assess macrophage infiltration. The macrophages were manually counted in three randomly selected fields per section of total nine sites per group. Scale bars, 100 μm. The bar graphs present the mean and SEM. ∗∗∗∗p < 0.0001 vs. untreated controls. ### p < 0.001 and #### p < 0.0001 vs. PB101-untreated positive controls. The p-values were determined via Kruskal–Wallis with Dunn's multiple comparisons test.
    Plgf 2, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+plgf+2/Recombinant+Mouse+PlGF-2+Protein/pmc13015212-72-20-25
    Average 94 stars, based on 1 article reviews
    plgf 2 - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    placental growth factor  (R&D Systems)
    93
    R&D Systems placental growth factor
    Inhibitory effects of PB101 on angiogenesis. ( A ) Endothelial cell chemotactic migration assay. EA.hy926 cells (1 × 10 5 , n = 3) were loaded in the upper chambers of Transwell inserts and chemoattracted by VEGF (100 ng/mL) <t>or</t> <t>PlGF-2</t> (40 ng/mL) with or without PB101 (2 or 5 μg/mL) in the lower chambers. The cells that migrated to the underside of the Transwell chamber were manually counted, and the results are presented as a percentage of the untreated control (none). ( B ) Wounding migration of endothelial cells. EA.hy926 cells (4 × 10 5 , n = 5) seeded on a 6-well plate were wounded using pipette tips and treated with VEGF (200 ng/mL) or PlGF-2 (100 ng/mL) with or without PB101 (2 or 5 μg/mL). The cells that crossed the reference lines (red dashed lines) were counted as migrated cells. ( C ) Capillary tube formation by endothelial cells. EA.hy926 cells (3 × 10 4 , n = 3–4) were seeded on a Matrigel-coated 96-well plate and incubated with VEGF (500 ng/mL) or PlGF-2 (500 ng/mL) with or without PB101 (10 or 50 μg/mL). The tube formation area was measured and is presented as an arbitrary unit (a.u.). The cellular images are representative of three independent experiments. Scale bar, 200 μm. The bar graphs present the mean and SEM. The p-values were determined via one-way ANOVA with Tukey's multiple comparisons test. ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001 vs. untreated controls. # p < 0.05, ## p < 0.01 vs. PlGF- or VEGF-treated positive controls. ( D and E ) Suppression of recombinant PlGF-induced angiogenesis by PB101 in a Matrigel plug assay. C57BL/6 mice (n = 3, total 12 mice) were injected subcutaneously with Matrigel mixed with VEGF (500 ng/mL) or recombinant PlGF-2 (200 ng/mL) with or without PB101 (50 μg/mL) (D). Mice were injected with vehicle or PB101 (50 mg/kg) every day. To assess the effects of PlGF-overexpressing T cells, CD4 + T cells isolated from PlGF transgenic (PlGF Tg) mice were stimulated with anti-CD3/CD28 Abs for 48 h. PlGF Tg CD4 + T cells (5 × 10 5 ) and their culture supernatants were incorporated into Matrigel with or without PB101 (50 μg/mL) (E). C57BL/6 mice (n = 3) were subcutaneously injected with these Matrigel plugs and received daily injections of Fc vehicle or PB101 (50 mg/kg). After 14 days, the vascularity of the Matrigel plugs was evaluated through visual assessment and H&E staining of the tissue sections. Scale bars, 500 nm (top) for Matrigel plugs, and 100 (middle) and 1000 (bottom) μm for H&E. The boxed areas in the upper panels of the H&E-stained images are shown at higher magnification in the lower panels. ( F ) Immunohistochemical staining of the Matrigel plugs was performed using an anti-F4/80 Ab to assess macrophage infiltration. The macrophages were manually counted in three randomly selected fields per section of total nine sites per group. Scale bars, 100 μm. The bar graphs present the mean and SEM. ∗∗∗∗p < 0.0001 vs. untreated controls. ### p < 0.001 and #### p < 0.0001 vs. PB101-untreated positive controls. The p-values were determined via Kruskal–Wallis with Dunn's multiple comparisons test.
    Placental Growth Factor, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+plgf+2/Mouse+PlGF-2+Quantikine+ELISA+Kit/pm41165539-200-0-4
    Average 93 stars, based on 1 article reviews
    placental growth factor - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier
    recombinant plgf mice  (R&D Systems)
    93
    R&D Systems recombinant plgf mice
    Figure 3. TAC stimulates splenic <t>PlGF</t> secretion to induce cardiac RM proliferation and counteract HF (A and B) Serial LV echocardiography in basal condition and 1–2–4–8 weeks after TAC in Cx3cr1/ and WT mice. EF (A) and RWT (B) are shown. n = 4 WT TAC; n = 5 Cx3cr1/ TAC. Data as mean ± SEM and analyzed by two-way ANOVA and Sidak post hoc. ***p < 0.001.
    Recombinant Plgf Mice, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+plgf+2/Recombinant+Mouse+PlGF-2+Protein%2C+CF/pm40023160-637-4-25
    Average 93 stars, based on 1 article reviews
    recombinant plgf mice - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier
    high sensitivity elisa kit  (R&D Systems)
    93
    R&D Systems high sensitivity elisa kit
    Figure 3. TAC stimulates splenic <t>PlGF</t> secretion to induce cardiac RM proliferation and counteract HF (A and B) Serial LV echocardiography in basal condition and 1–2–4–8 weeks after TAC in Cx3cr1/ and WT mice. EF (A) and RWT (B) are shown. n = 4 WT TAC; n = 5 Cx3cr1/ TAC. Data as mean ± SEM and analyzed by two-way ANOVA and Sidak post hoc. ***p < 0.001.
    High Sensitivity Elisa Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+plgf+2/Mouse+PlGF-2+Quantikine+ELISA+Kit/pm40023160-676-48-52
    Average 93 stars, based on 1 article reviews
    high sensitivity elisa kit - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier
    mouse plgf 2 concentration  (R&D Systems)
    93
    R&D Systems mouse plgf 2 concentration
    Figure 3. TAC stimulates splenic <t>PlGF</t> secretion to induce cardiac RM proliferation and counteract HF (A and B) Serial LV echocardiography in basal condition and 1–2–4–8 weeks after TAC in Cx3cr1/ and WT mice. EF (A) and RWT (B) are shown. n = 4 WT TAC; n = 5 Cx3cr1/ TAC. Data as mean ± SEM and analyzed by two-way ANOVA and Sidak post hoc. ***p < 0.001.
    Mouse Plgf 2 Concentration, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+plgf+2/Mouse+PlGF-2+Quantikine+ELISA+Kit/pm38971073-51-14-24
    Average 93 stars, based on 1 article reviews
    mouse plgf 2 concentration - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier
    serum plgf  (R&D Systems)
    93
    R&D Systems serum plgf
    Figure 3. TAC stimulates splenic <t>PlGF</t> secretion to induce cardiac RM proliferation and counteract HF (A and B) Serial LV echocardiography in basal condition and 1–2–4–8 weeks after TAC in Cx3cr1/ and WT mice. EF (A) and RWT (B) are shown. n = 4 WT TAC; n = 5 Cx3cr1/ TAC. Data as mean ± SEM and analyzed by two-way ANOVA and Sidak post hoc. ***p < 0.001.
    Serum Plgf, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+plgf+2/Mouse+PlGF-2+Quantikine+ELISA+Kit/pm39173826-71-0-2
    Average 93 stars, based on 1 article reviews
    serum plgf - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier
    pgf  (R&D Systems)
    93
    R&D Systems pgf
    Figure 2. Talazoparib (Tal)-resistant tumors show increased <t>VEGFR2</t> <t>(KDR)</t> and <t>PGF</t> expression but only modest sensitization to Tal upon VEGFR2 depletion.
    Pgf, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+plgf+2/Mouse+PlGF-2+Antibody/pm38956205-220-49-52
    Average 93 stars, based on 1 article reviews
    pgf - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier
    mouse recombinant pgf  (R&D Systems)
    94
    R&D Systems mouse recombinant pgf
    Figure 2. Talazoparib (Tal)-resistant tumors show increased <t>VEGFR2</t> <t>(KDR)</t> and <t>PGF</t> expression but only modest sensitization to Tal upon VEGFR2 depletion.
    Mouse Recombinant Pgf, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+plgf+2/Recombinant+Mouse+PlGF-2+Protein/pm38956205-251-38-41
    Average 94 stars, based on 1 article reviews
    mouse recombinant pgf - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    anti pigf 2  (R&D Systems)
    92
    R&D Systems anti pigf 2
    Figure 2. Talazoparib (Tal)-resistant tumors show increased <t>VEGFR2</t> <t>(KDR)</t> and <t>PGF</t> expression but only modest sensitization to Tal upon VEGFR2 depletion.
    Anti Pigf 2, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+plgf+2/Mouse+PlGF-2+Antibody/bio_rxiv__2024__07__12__603312-137-14-18
    Average 92 stars, based on 1 article reviews
    anti pigf 2 - by Bioz Stars, 2026-10
    92/100 stars
    		  Buy from Supplier

    Image Search Results


    Inhibitory effects of PB101 on angiogenesis. ( A ) Endothelial cell chemotactic migration assay. EA.hy926 cells (1 × 10 5 , n = 3) were loaded in the upper chambers of Transwell inserts and chemoattracted by VEGF (100 ng/mL) or PlGF-2 (40 ng/mL) with or without PB101 (2 or 5 μg/mL) in the lower chambers. The cells that migrated to the underside of the Transwell chamber were manually counted, and the results are presented as a percentage of the untreated control (none). ( B ) Wounding migration of endothelial cells. EA.hy926 cells (4 × 10 5 , n = 5) seeded on a 6-well plate were wounded using pipette tips and treated with VEGF (200 ng/mL) or PlGF-2 (100 ng/mL) with or without PB101 (2 or 5 μg/mL). The cells that crossed the reference lines (red dashed lines) were counted as migrated cells. ( C ) Capillary tube formation by endothelial cells. EA.hy926 cells (3 × 10 4 , n = 3–4) were seeded on a Matrigel-coated 96-well plate and incubated with VEGF (500 ng/mL) or PlGF-2 (500 ng/mL) with or without PB101 (10 or 50 μg/mL). The tube formation area was measured and is presented as an arbitrary unit (a.u.). The cellular images are representative of three independent experiments. Scale bar, 200 μm. The bar graphs present the mean and SEM. The p-values were determined via one-way ANOVA with Tukey's multiple comparisons test. ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001 vs. untreated controls. # p < 0.05, ## p < 0.01 vs. PlGF- or VEGF-treated positive controls. ( D and E ) Suppression of recombinant PlGF-induced angiogenesis by PB101 in a Matrigel plug assay. C57BL/6 mice (n = 3, total 12 mice) were injected subcutaneously with Matrigel mixed with VEGF (500 ng/mL) or recombinant PlGF-2 (200 ng/mL) with or without PB101 (50 μg/mL) (D). Mice were injected with vehicle or PB101 (50 mg/kg) every day. To assess the effects of PlGF-overexpressing T cells, CD4 + T cells isolated from PlGF transgenic (PlGF Tg) mice were stimulated with anti-CD3/CD28 Abs for 48 h. PlGF Tg CD4 + T cells (5 × 10 5 ) and their culture supernatants were incorporated into Matrigel with or without PB101 (50 μg/mL) (E). C57BL/6 mice (n = 3) were subcutaneously injected with these Matrigel plugs and received daily injections of Fc vehicle or PB101 (50 mg/kg). After 14 days, the vascularity of the Matrigel plugs was evaluated through visual assessment and H&E staining of the tissue sections. Scale bars, 500 nm (top) for Matrigel plugs, and 100 (middle) and 1000 (bottom) μm for H&E. The boxed areas in the upper panels of the H&E-stained images are shown at higher magnification in the lower panels. ( F ) Immunohistochemical staining of the Matrigel plugs was performed using an anti-F4/80 Ab to assess macrophage infiltration. The macrophages were manually counted in three randomly selected fields per section of total nine sites per group. Scale bars, 100 μm. The bar graphs present the mean and SEM. ∗∗∗∗p < 0.0001 vs. untreated controls. ### p < 0.001 and #### p < 0.0001 vs. PB101-untreated positive controls. The p-values were determined via Kruskal–Wallis with Dunn's multiple comparisons test.

    Journal: eBioMedicine

    Article Title: The therapeutic effects of the VEGF decoy receptor fusion protein VEGF-Grab in chronic inflammatory diseases

    doi: 10.1016/j.ebiom.2026.106216

    Figure Lengend Snippet: Inhibitory effects of PB101 on angiogenesis. ( A ) Endothelial cell chemotactic migration assay. EA.hy926 cells (1 × 10 5 , n = 3) were loaded in the upper chambers of Transwell inserts and chemoattracted by VEGF (100 ng/mL) or PlGF-2 (40 ng/mL) with or without PB101 (2 or 5 μg/mL) in the lower chambers. The cells that migrated to the underside of the Transwell chamber were manually counted, and the results are presented as a percentage of the untreated control (none). ( B ) Wounding migration of endothelial cells. EA.hy926 cells (4 × 10 5 , n = 5) seeded on a 6-well plate were wounded using pipette tips and treated with VEGF (200 ng/mL) or PlGF-2 (100 ng/mL) with or without PB101 (2 or 5 μg/mL). The cells that crossed the reference lines (red dashed lines) were counted as migrated cells. ( C ) Capillary tube formation by endothelial cells. EA.hy926 cells (3 × 10 4 , n = 3–4) were seeded on a Matrigel-coated 96-well plate and incubated with VEGF (500 ng/mL) or PlGF-2 (500 ng/mL) with or without PB101 (10 or 50 μg/mL). The tube formation area was measured and is presented as an arbitrary unit (a.u.). The cellular images are representative of three independent experiments. Scale bar, 200 μm. The bar graphs present the mean and SEM. The p-values were determined via one-way ANOVA with Tukey's multiple comparisons test. ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001 vs. untreated controls. # p < 0.05, ## p < 0.01 vs. PlGF- or VEGF-treated positive controls. ( D and E ) Suppression of recombinant PlGF-induced angiogenesis by PB101 in a Matrigel plug assay. C57BL/6 mice (n = 3, total 12 mice) were injected subcutaneously with Matrigel mixed with VEGF (500 ng/mL) or recombinant PlGF-2 (200 ng/mL) with or without PB101 (50 μg/mL) (D). Mice were injected with vehicle or PB101 (50 mg/kg) every day. To assess the effects of PlGF-overexpressing T cells, CD4 + T cells isolated from PlGF transgenic (PlGF Tg) mice were stimulated with anti-CD3/CD28 Abs for 48 h. PlGF Tg CD4 + T cells (5 × 10 5 ) and their culture supernatants were incorporated into Matrigel with or without PB101 (50 μg/mL) (E). C57BL/6 mice (n = 3) were subcutaneously injected with these Matrigel plugs and received daily injections of Fc vehicle or PB101 (50 mg/kg). After 14 days, the vascularity of the Matrigel plugs was evaluated through visual assessment and H&E staining of the tissue sections. Scale bars, 500 nm (top) for Matrigel plugs, and 100 (middle) and 1000 (bottom) μm for H&E. The boxed areas in the upper panels of the H&E-stained images are shown at higher magnification in the lower panels. ( F ) Immunohistochemical staining of the Matrigel plugs was performed using an anti-F4/80 Ab to assess macrophage infiltration. The macrophages were manually counted in three randomly selected fields per section of total nine sites per group. Scale bars, 100 μm. The bar graphs present the mean and SEM. ∗∗∗∗p < 0.0001 vs. untreated controls. ### p < 0.001 and #### p < 0.0001 vs. PB101-untreated positive controls. The p-values were determined via Kruskal–Wallis with Dunn's multiple comparisons test.

    Article Snippet: Next, the cells were treated for 12 h with medium containing VEGF (200 ng/mL; catalog 100-20; Peprotech, Cranbury, NJ) or PlGF-2 (100 ng/mL; catalog 465-PL; R&D Systems, Minneapolis, MN) with or without PB101 (2, 5, or 10 μg/mL) and supplemented with 1% FBS for EA.hy926 cells and 0.1% FBS for RA-FLSs.

    Techniques: Migration, Control, Transferring, Incubation, Recombinant, Matrigel Assay, Injection, Isolation, Transgenic Assay, Staining, Immunohistochemical staining

    Suppressive effects of VEGF-Grab on the aggressiveness of RA-FLSs. ( A ) Chemotactic migration of RA-FLSs in Transwell inserts. RA-FLSs (1 × 10 5 , n = 4) were loaded in the upper chambers of Transwell inserts. Culture media supplemented with 1% FBS and recombinant PlGF-2 (100 ng/mL), with or without PB101 (5 or 10 μg/mL), were loaded in the lower chamber. After 12 h, cells that migrated to the lower side of the Transwell membrane were manually counted. Scale bars, 1000 μm (upper panel) and 200 μm (lower panel). ( B ) Wounding migration assay with RA-FLSs. RA-FLSs (1.5 × 10 5 , n = 4) were seeded on 6-well plates, scratched with pipette tips, and treated with recombinant PlGF-2 (100 ng/mL), with and without PB101 (2 or 10 μg/mL), for 12 h. The cells that migrated across the reference lines (red dashed lines) were manually counted. Scale bars, 200 μm. The bar graphs present the mean and SEM. ∗∗p < 0.01 vs. untreated controls. # p < 0.05 and ## p < 0.01 vs. PlGF-treated positive controls. The p-values were determined via one-way ANOVA with Tukey's multiple comparisons test. ( C ) RA-FLS invasion into cartilage in a humanised synovitis model. RA-FLSs (2 × 10 6 ) were resuspended in a medium containing PlGF-2 (100 ng/mL) or a medium with PlGF-2 (100 ng/mL) and PB101 (2 μg/mL). These RA-FLSs were co-implanted with human cartilage into the left flanks (primary) of SCID mice (n = 3, total 6 mice). In the right flanks (contralateral), cartilage of the same size was implanted without RA-FLSs. For 60 days after cartilage implantation, the mice were injected intraperitoneally with vehicle or PB101 (2 mg/kg) twice a week. ( D ) Following excision, the cartilage samples were processed for H&E staining to evaluate invasion. The scoring protocol is detailed in the Materials and Methods section. For each implanted cartilage, three distinct regions were evaluated independently, and all regional values are shown as individual data points. Scale bars, 100 μm. The bar graphs present the mean and SEM. ∗p < 0.05 vs. vehicle controls. The p-values were determined via an unpaired t -test.

    Journal: eBioMedicine

    Article Title: The therapeutic effects of the VEGF decoy receptor fusion protein VEGF-Grab in chronic inflammatory diseases

    doi: 10.1016/j.ebiom.2026.106216

    Figure Lengend Snippet: Suppressive effects of VEGF-Grab on the aggressiveness of RA-FLSs. ( A ) Chemotactic migration of RA-FLSs in Transwell inserts. RA-FLSs (1 × 10 5 , n = 4) were loaded in the upper chambers of Transwell inserts. Culture media supplemented with 1% FBS and recombinant PlGF-2 (100 ng/mL), with or without PB101 (5 or 10 μg/mL), were loaded in the lower chamber. After 12 h, cells that migrated to the lower side of the Transwell membrane were manually counted. Scale bars, 1000 μm (upper panel) and 200 μm (lower panel). ( B ) Wounding migration assay with RA-FLSs. RA-FLSs (1.5 × 10 5 , n = 4) were seeded on 6-well plates, scratched with pipette tips, and treated with recombinant PlGF-2 (100 ng/mL), with and without PB101 (2 or 10 μg/mL), for 12 h. The cells that migrated across the reference lines (red dashed lines) were manually counted. Scale bars, 200 μm. The bar graphs present the mean and SEM. ∗∗p < 0.01 vs. untreated controls. # p < 0.05 and ## p < 0.01 vs. PlGF-treated positive controls. The p-values were determined via one-way ANOVA with Tukey's multiple comparisons test. ( C ) RA-FLS invasion into cartilage in a humanised synovitis model. RA-FLSs (2 × 10 6 ) were resuspended in a medium containing PlGF-2 (100 ng/mL) or a medium with PlGF-2 (100 ng/mL) and PB101 (2 μg/mL). These RA-FLSs were co-implanted with human cartilage into the left flanks (primary) of SCID mice (n = 3, total 6 mice). In the right flanks (contralateral), cartilage of the same size was implanted without RA-FLSs. For 60 days after cartilage implantation, the mice were injected intraperitoneally with vehicle or PB101 (2 mg/kg) twice a week. ( D ) Following excision, the cartilage samples were processed for H&E staining to evaluate invasion. The scoring protocol is detailed in the Materials and Methods section. For each implanted cartilage, three distinct regions were evaluated independently, and all regional values are shown as individual data points. Scale bars, 100 μm. The bar graphs present the mean and SEM. ∗p < 0.05 vs. vehicle controls. The p-values were determined via an unpaired t -test.

    Article Snippet: Next, the cells were treated for 12 h with medium containing VEGF (200 ng/mL; catalog 100-20; Peprotech, Cranbury, NJ) or PlGF-2 (100 ng/mL; catalog 465-PL; R&D Systems, Minneapolis, MN) with or without PB101 (2, 5, or 10 μg/mL) and supplemented with 1% FBS for EA.hy926 cells and 0.1% FBS for RA-FLSs.

    Techniques: Migration, Recombinant, Membrane, Transferring, Injection, Staining

    Figure 3. TAC stimulates splenic PlGF secretion to induce cardiac RM proliferation and counteract HF (A and B) Serial LV echocardiography in basal condition and 1–2–4–8 weeks after TAC in Cx3cr1/ and WT mice. EF (A) and RWT (B) are shown. n = 4 WT TAC; n = 5 Cx3cr1/ TAC. Data as mean ± SEM and analyzed by two-way ANOVA and Sidak post hoc. ***p < 0.001.

    Journal: Immunity

    Article Title: A heart-brain-spleen axis controls cardiac remodeling to hypertensive stress.

    doi: 10.1016/j.immuni.2025.02.013

    Figure Lengend Snippet: Figure 3. TAC stimulates splenic PlGF secretion to induce cardiac RM proliferation and counteract HF (A and B) Serial LV echocardiography in basal condition and 1–2–4–8 weeks after TAC in Cx3cr1/ and WT mice. EF (A) and RWT (B) are shown. n = 4 WT TAC; n = 5 Cx3cr1/ TAC. Data as mean ± SEM and analyzed by two-way ANOVA and Sidak post hoc. ***p < 0.001.

    Article Snippet: In vivo administration of recombinant PlGF Mice subjected to splenectomy have been treated by intraperitoneal injection of 1,5 mg/Kg body weight of recombinant PlGF (rPlGF) (R&D Systems) and with NaCl 0.9% as vehicle control as previously described.14 Follow up analysis of cardiac remodeling has been performed by echocardiography.

    Techniques:

    Figure 4. Splenic-derived PlGF promotes the expansion of RMs and hinders HF (A and B) Immunofluorescence (A) and quantification (B) of PlGF in the splenic marginal zone delimited by ERTR7+ fibroblast reticular cells in sham or TAC mice subjected to CGX or control (scale bar, 50 mm). n = 6 sham; n = 5 TAC; n = 5 TAC CGX. Data as mean ± SEM and analyzed by one-way ANOVA and Tukey post hoc. *p < 0.05. (legend continued on next page)

    Journal: Immunity

    Article Title: A heart-brain-spleen axis controls cardiac remodeling to hypertensive stress.

    doi: 10.1016/j.immuni.2025.02.013

    Figure Lengend Snippet: Figure 4. Splenic-derived PlGF promotes the expansion of RMs and hinders HF (A and B) Immunofluorescence (A) and quantification (B) of PlGF in the splenic marginal zone delimited by ERTR7+ fibroblast reticular cells in sham or TAC mice subjected to CGX or control (scale bar, 50 mm). n = 6 sham; n = 5 TAC; n = 5 TAC CGX. Data as mean ± SEM and analyzed by one-way ANOVA and Tukey post hoc. *p < 0.05. (legend continued on next page)

    Article Snippet: In vivo administration of recombinant PlGF Mice subjected to splenectomy have been treated by intraperitoneal injection of 1,5 mg/Kg body weight of recombinant PlGF (rPlGF) (R&D Systems) and with NaCl 0.9% as vehicle control as previously described.14 Follow up analysis of cardiac remodeling has been performed by echocardiography.

    Techniques: Derivative Assay, Control

    Figure 6. PlGF-NRP1 mediates adaptive functions of macrophages during pressure overload (A and B) Flow cytometry (A) and quantification (B) of NRP1 expression in cardiac Ly6CloTimd4Lyve-1+ RMs after TAC. n = 6 sham; n = 7 TAC. Data as mean ± SEM and analyzed by unpaired t test. ***p < 0.001.

    Journal: Immunity

    Article Title: A heart-brain-spleen axis controls cardiac remodeling to hypertensive stress.

    doi: 10.1016/j.immuni.2025.02.013

    Figure Lengend Snippet: Figure 6. PlGF-NRP1 mediates adaptive functions of macrophages during pressure overload (A and B) Flow cytometry (A) and quantification (B) of NRP1 expression in cardiac Ly6CloTimd4Lyve-1+ RMs after TAC. n = 6 sham; n = 7 TAC. Data as mean ± SEM and analyzed by unpaired t test. ***p < 0.001.

    Article Snippet: In vivo administration of recombinant PlGF Mice subjected to splenectomy have been treated by intraperitoneal injection of 1,5 mg/Kg body weight of recombinant PlGF (rPlGF) (R&D Systems) and with NaCl 0.9% as vehicle control as previously described.14 Follow up analysis of cardiac remodeling has been performed by echocardiography.

    Techniques: Flow Cytometry, Expressing

    Figure 2. Talazoparib (Tal)-resistant tumors show increased VEGFR2 (KDR) and PGF expression but only modest sensitization to Tal upon VEGFR2 depletion.

    Journal: EMBO molecular medicine

    Article Title: FLT1 activation in cancer cells promotes PARP-inhibitor resistance in breast cancer.

    doi: 10.1038/s44321-024-00094-2

    Figure Lengend Snippet: Figure 2. Talazoparib (Tal)-resistant tumors show increased VEGFR2 (KDR) and PGF expression but only modest sensitization to Tal upon VEGFR2 depletion.

    Article Snippet: The slides were further blocked with BSA and goat or rabbit serum (depending on the species of the secondary antibodies), and tissue sections were incubated with primary antibodies, including antibodies against phospho-AKT (S473) (1:100, #4060, Cell Signaling Technology), KDR/VEGFR2 (1:2000, #9698, Cell Signaling Technology), VEGFA (1:300, #AF-493-NA, R&D Systems), PGF (1:300, AF465, R&D Systems), CD8α (1:200, #98941, Cell Signaling Technology), F4/80 (1:500, #70076, Cell Signaling Technology), B220 (1:400, # 553085, BD Pharmingen), CD4 (1:200, #25229, Cell Signaling Technology), CD11C (1:250, #97585, Cell Signaling Technology), FOXP3 (1:100, #12653, Cell Signaling Technology), murine S100A9 (1:1000, #73425, Cell Signaling Technology), FLT4 (1:250, #AF743, R&D Systems), and phospho-Stat3 (S727) (1:100, #9134, Cell Signaling Technology), followed by incubation with the corresponding biotinylated secondary antibodies (1:250, Vector Laboratories).

    Techniques: Expressing